Abstract
Current information suggests that in patients with congestive heart failure (CHF) who have asymptomatic ventricular arrhythmias, coronary artery disease (dilated ischemic cardiomyopathy), and a positive signal-averaged electrocardiogram, electrophysiologic studies are useful for stratifying risk and guiding therapy. Therapy with amiodarone hydrochloride (Cordarone) appears to improve survival in patients after myocardial infarction. In CHF patients with asymptomatic ventricular arrhythmias and dilated nonischemic cardiomyopathy, electrophysiologic studies are of little value in risk stratification because of their low yield of sustained monomorphic tachycardias. There is little evidence that therapy with conventional antiarrhythmic agents improves survival. Although amiodarone can suppress ventricular ectopic beats, no trial yet conducted has detected an effect on mortality. Randomized, controlled trials with low-dose amiodarone are needed for more definitive information. Most symptomatic patients should undergo electrophysiologic testing and receive guided therapy, either with antiarrhythmic drugs or with an implantable cardioverter-defibrillator.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
